BTC$59,122.00-1.06%
ETH$1,558.70-1.78%
USDT$0.9986+0.00%
BNB$553.00-0.29%
USDC$0.9996-0.01%
XRP$1.03-2.54%
SOL$65.85-0.94%
TRX$0.3235-0.67%
FIGR_HELOC$1.03-0.49%
HYPE$61.33+2.82%
DOGE$0.0734-1.03%
USDS$0.9996+0.00%
RAIN$0.0157-0.45%
LEO$9.35-0.70%
ZEC$396.61-0.83%
XLM$0.1764-4.24%
BTC$59,122.00-1.06%
ETH$1,558.70-1.78%
USDT$0.9986+0.00%
BNB$553.00-0.29%
USDC$0.9996-0.01%
XRP$1.03-2.54%
SOL$65.85-0.94%
TRX$0.3235-0.67%
FIGR_HELOC$1.03-0.49%
HYPE$61.33+2.82%
DOGE$0.0734-1.03%
USDS$0.9996+0.00%
RAIN$0.0157-0.45%
LEO$9.35-0.70%
ZEC$396.61-0.83%
XLM$0.1764-4.24%
Netflix fell in premarket despite beating Q4 estimates, as weaker growth trends and the Warner Bros. Discovery deal overhang pressured sentiment.
Despite surpassing its average analyst price target, Micron’s forward valuation and memory bottleneck economics point toward a credible path to $500 by 2026.
RAPT Therapeutics stock surged over 63% after GSK agreed to buy the company for $58 per share in a $2.2 billion deal.
With risk assets retreating and commodities exploding higher, investors are hunting for durable growth stories trading below consensus value.
ImmunityBio shares jumped in premarket trading after the FDA outlined next steps for expanding ANKTIVA’s bladder cancer label.
Critical Metals stock jumped in premarket trading as fresh headlines around Greenland reignited investor interest in the company’s Tanbreez rare earths project.
State Street shares slipped after the bank posted a Q4 earnings and revenue beat, but investors focused on restructuring costs and a higher-than-expected expense outlook for…
QXO stock declined over 6% in premarket trading after announcing a 31.6 million share offering priced at $23.80, below its previous close.
Regions Financial shares fell sharply in premarket trading after the bank reported fourth-quarter earnings that came in below Wall Street expectations.
ImmunityBio stock jumped after the company reported preliminary 2025 net product revenue of $113 million, up about 700% year over year.
Morgan Stanley stock rose over 4% after the bank beat Q4 estimates, posting $2.68 EPS on $17.89 billion in revenue as investment banking revenue jumped 47%.
With financials outperforming in the past year, we analyze the largest KBWB constituents to determine which bank combines earnings strength with the highest upside potential.
Boston Scientific stock slipped 3.6% in premarket trading after the company announced a $14.5 billion deal to buy Penumbra.